Peripheral sensory disturbances related to treatment with fluoroquinolones

Hedenmalm, Karin; Spigset, Olav

doi:10.1093/jac/37.4.831

Cited by 30 publications

(24 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31 The only previous report in the medical literature involving more than a few cases of fluoroquinolone-related neuropathies was published in 1996 by the Swedish Adverse Drug Reactions Advisory Committee. 17 This report listed 37 cases of peripheral sensory disturbances submitted to the Swedish authorities over a period of seven years (1987)(1988)(1989)(1990)(1991)(1992)(1993). Most of these events were mild and brief.…”

Section: Neurotoxicity and Fluoroquinolone Antibioticsmentioning

confidence: 99%

Peripheral Neuropathy Associated with Fluoroquinolones

Cohen

2001

Ann Pharmacother

View full text Add to dashboard Cite

These cases suggest a possible association between fluoroquinolone antibiotics and severe, long-term adverse effects involving the PNS as well as other organ systems. The severity of these cases may reflect a different population than typically reported to drug companies or MedWatch, which often originate from healthcare providers. In contrast, Internet Web sites may provide a forum for patients experiencing adverse effects that have not resolved promptly. Further study is warranted. Meanwhile the occurrence of PNS symptoms during fluoroquinolone therapy should prompt immediate discontinuation of the agent used.

show abstract

Section: Neurotoxicity and Fluoroquinolone Antibioticsmentioning

confidence: 99%

Peripheral Neuropathy Associated with Fluoroquinolones

Cohen

2001

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…3 In 1996, the Swedish Adverse Drug Reactions Advisory Committee reported 37 cases of peripheral sensory disturbance relating to the quinolones between 1985 and 1993. 4 In 68% of patients, symptoms occurred within one week after starting treatment. Paraesthesia was the most common complaint.…”

Section: Discussion and Literature Reviewmentioning

confidence: 99%

Ciprofloxacin Induced Acute Small Fibre Neuropathy. Case Report

Jumma

Dick

Mellor

2013

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

“…El año 2013 la Agencia Norteamericana de Alimentos y Medicamentos de E.U.A., emitió un comunicado indicando que todos los folletos de información de fluoroquinolonas debían colocar la neuropatía periférica como un efecto adverso grave, aunque infrecuente 35 . El inicio de síntomas tiene una latencia variable, pero más de la mitad de los pacientes inician síntomas dentro de la semana de uso 36,37 . La sintomatología presentada es bien amplia, con síntomas sensoriales más que motores, destacando entre las alteraciones sensoriales: parestesias, entumecimiento, dolor urente, sensación de agujas o golpes eléctricos, hiperestesia, hipoestesia y alodinia; y entre las alteraciones motoras: debilidad, fasciculaciones, temblores, espasmos y contracciones 37 .…”

Section: Sistema Nervioso Periféricounclassified

Seguridad de las fluoroquinolonas: riesgos habitualmente olvidados para el clínico

Pavez

et al. 2017

Rev. chil. infectol.

View full text Add to dashboard Cite

Safety of fluoroquinolones: risks usually forgotten for the clinicianQuinolones are a group of widely used antimicrobials. Although they are considered safe for patients, knowledge of the safety profile is necessary so that professionals become aware of what is necessary to monitor. At the musculoskeletal level, quinolones have the potential to damage cartilage, causing even tendon rupture in infrequent cases. Hypoglycemia / hyperglycemia has been observed at the endocrine level, thus, careful monitoring of glycemia in patients with quinolone is recommended in diabetic patients. At the cardiovascular level, arrhythmias induced by these antimicrobials are rare but severe. At the level of the nervous system, the appearance of alterations of the central nervous system and the peripheral neuropathy are emphasized. When assessing the safety of quinolones, it is important to consider potential interactions with other substances (medical products). In children it is preferred not to use fluoroquinolones because of the potential risk of cartilage damage and growth, effects that do not seem to be so dramatic in the face of new evidence. Despite optimism, the safety of the treatment of these antimicrobials should be evaluated in every pediatric patient.Key words: Fluoroquinolonas, safety, pharmaco surveillance, pediatrics. Palabras clave: Fluoroquinolonas, seguridad, farmacovigilancia, pediatría. IntroducciónL as quinolonas son un grupo de antimicrobianos que ha presentado un aumento progresivo de consumo ambulatorio a través de los años 1 . Gracias a la farmacovigilancia se han detectado reacciones adversas graves que han obligado a retirar del mercado varias fluoroquinolonas 2 . Por ejemplo, grepafloxacina experimentó un retiro voluntario por el efecto de prolongación del intervalo QT, complicación que exponía a los pacientes a riesgo de arritmias ventriculares graves, como la torsión de puntas 3 . Otro ejemplo fue el retiro de gatifloxacina, por alteraciones en los valores de glicemia 4 . El reporte de las reacciones adversas a medicamento a la autoridad regulatoria es un factor clave para la detección oportuna de eventos adversos en nuestra población. Si bien el grupo de las quinolonas es considerado seguro para los pacientes, el conocimiento del perfil de seguridad es necesario para que los profesionales estén en conocimiento de lo que es necesario reportar. Los efectos adversos más frecuentes de las quinolonas son los gastrointestinales (náuseas, vó-mitos, diarrea), las alergias y las reacciones neurológicas (mareo, cefalea, ansiedad) 5 . En los últimos años algunas agencias sanitarias de países desarrollados han emitido alertas de seguridad por reacciones adversas a este grupo de medicamentos y, a pesar de que estos eventos son incluidos en los folletos de información al profesional, son desconocidos para los médicos clínicos.El objetivo de la presente revisión es dar a conocer reacciones adversas de las fluoroquinolonas que han adquirido relevancia clínica en los últimos años, con la intención de que sean detectad...

show abstract

Peripheral sensory disturbances related to treatment with fluoroquinolones

Cited by 30 publications

References 7 publications

Peripheral Neuropathy Associated with Fluoroquinolones

Peripheral Neuropathy Associated with Fluoroquinolones

Ciprofloxacin Induced Acute Small Fibre Neuropathy. Case Report

Seguridad de las fluoroquinolonas: riesgos habitualmente olvidados para el clínico

Contact Info

Product

Resources

About